| |
Oxford
BioMedica (LSE: OXB) is a biopharmaceutical
company specialising in the development
of novel gene-based therapeutics with a
focus on oncology and neurotherapy. The
Company was established in 1995 as a spin
out from Oxford University, and is listed
on the London Stock Exchange.
Oxford
BioMedica has core expertise in gene delivery,
as well as in-house clinical, regulatory
and manufacturing know-how. In oncology,
the pipeline includes two candidates in
multiple Phase II trials, and a preclinical
targeted antibody therapy in collaboration
with Wyeth. A Phase III trial in renal cancer
with TroVax, the lead cancer immunotherapy
candidate, is expected to start in the second
half of 2006. In neurotherapy, the Company's
lead product is a gene therapy for Parkinson's
disease, which is expected to enter clinical
development in 2006, and four further preclinical
candidates. The Company is underpinned by
over 80 patent families, which represent
one of the broadest patent estates in the
field.
The
Company has a staff of approximately 70
split between its main facilities in Oxford
and its wholly owned subsidiary, BioMedica
Inc, in San Diego, California. Oxford BioMedica
has corporate collaborations with Wyeth,
Intervet, Sigma-Aldrich, Viragen, MolMed,
Virxsys and Kiadis; and has licensed technology
to a number of companies including Merck
& Co, Biogen Idec and Pfizer. |
